Skip to main content

Follicular Lymphoma, EZH2 Mutation, COBAS

Test code(s) 39928

The Follicular Lymphoma, EZH2 Mutation, COBAS test is a real-time, allele-specific PCR test approved by the US Food and Drug Administration (FDA) for the qualitative detection of common mutations in the enhancer of zeste 2 polycomb repressive complex 2 (EZH2) gene in patients with follicular lymphoma.1 Testing is performed on DNA extracted from formalin-fixed, paraffin-embedded (FFPE) follicular lymphoma tumor tissue and identifies the following variants: Y646N, Y646F or Y646X (Y646H, Y646S, or Y646C), A682G, and A692V.

Testing is performed on FFPE follicular lymphoma tumor tissue.

Results can be expected 7 days after specimen receipt.


  1. cobas® EZH2 Mutation Test. Package insert. Roche Diagnostics Inc; 2020.
  2. Bödör C, Grossmann V, Popov N, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013;122(18):3165-3168. doi:10.1182/blood-2013-04-496893
  3. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181-185. doi:10.1038/ng.518 TAZVERIK® (tazemetostat). Highlights of prescribing information. Epizyme Inc; 2020.
  4. TAZVERIK® (tazemetostat). Highlights of prescribing information. Epizyme Inc; 2020.


This FAQ is provided for informational purposes only and is not intended as medical advice. Test selection and interpretation, diagnosis, and patient management decisions should be based on the clinician’s education, clinical expertise, and assessment of the patient.

Document FAQS.263 Version: 0
Effective 06/14/2021 to present